Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | STAMBP | O95630 | 2/20 | 0.31 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.31 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6983110 | 0.89 | GABRA5 (0.32) | STAMBP | |
| SCHEMBL6985261 | 0.72 | CA2 (0.40) | CA2STAMBPPSMD14COPS5 | |
| SCHEMBL22059413 | 0.60 | STAMBP (0.51) | STAMBPPSMD14COPS5 | |
| SCHEMBL6981270 | 0.60 | PSMD14 (0.43) | STAMBPPSMD14COPS5 | |
| SCHEMBL7793476 | 0.60 | CFTR (0.38) | — | |
| SCHEMBL2305220 | 0.59 | CA2 (0.44) | CA2 | |
| SCHEMBL6980589 | 0.58 | P4HTM (0.48) | — | |
| SCHEMBL6577234 | 0.58 | LOXL2 (0.53) | CA2 | |
| SCHEMBL6975182 | 0.57 | L3MBTL1 (0.40) | — | |
| SCHEMBL6987201 | 0.57 | CCR1 (0.40) | PSMD14COPS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1027351-B1 | PHENANTHROLINE DERIVATIVES | FIBROGEN INC (US) | 2003-12-03 | — | — | EP | claimed |
| EP-1027351-B1 | PHENANTHROLINE DERIVATIVES | FIBROGEN INC (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20010001101-A1 | Phenanthroline derivatives | ZENECA LIMITED | 2001-05-10 | — | — | US | disclosed |
| US-6200974-B1 | FOR PRODUCING AN ANTI-FIBROPROLIFERATIVE EFFECT | ZENECA LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
| US-5916898-A | ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS | ZENECA LIMITED (GB) | 1999-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010001101-A1 | Phenanthroline derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 | CA2 29/4885STAMBP 4323/4885PSMD14 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.